Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Clinuvel Pharmaceuticals ( (AU:CUV) ).
Clinuvel Pharmaceuticals has reported new clinical data from four Fitzpatrick VI (darker skin type) adult patients enrolled in its ongoing CUV105 study evaluating SCENESSE® in vitiligo, presented at the Regional Dermatology Training Center conference in Tanzania. The patients, who completed a 140-day treatment regimen of seven SCENESSE® implants combined with up to 40 narrowband UVB sessions and were followed through day 224, tolerated the therapy well, expressed satisfaction with outcomes, and showed repigmentation patterns consistent with earlier cases, reinforcing the potential of the drug to restore pigmentation and identity in vitiligo patients and supporting Clinuvel’s decision to accelerate its clinical development program in this indication.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$14.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
More about Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals is a biopharmaceutical company focused on developing and commercialising photoprotective and pigmentation therapies, notably SCENESSE® (afamelanotide 16mg), for patients with dermatological and pigmentary disorders. The company targets niche indications with high unmet medical need, including conditions affecting skin pigmentation and photoprotection, with a particular emphasis on improving quality of life for patients with severe dermatologic diseases.
Average Trading Volume: 92,938
Technical Sentiment Signal: Hold
Current Market Cap: A$624M
For an in-depth examination of CUV stock, go to TipRanks’ Overview page.